Crinetics Pharmaceuticals 주식 (NASDAQ: CRNX)

에 대한 최신 뉴스 Crinetics Pharmaceuticals (NASDAQ:CRNX) 주식

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.

QuantumScape QS Stock

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals Inc

Keefe, Bruyette &amp; Woods analyst Bose George maintains First American Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FAF#NYSE">FAF</a>) with a Outperform and raises the price target from $75 to $77.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on First American Financial, Raises Price Target to $77

WIIM

SPCB

SuperCom shares are trading lower after the company reported worse-than-expected Q4 sales results.

RBC Capital analyst Paul Treiber reiterates Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Outperform and maintains $120 price target.

Reiteration

RBC Capital Reiterates Outperform on Celestica, Maintains $120 Price Target

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Eagle Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGBN#NASDAQ">EGBN</a>) with a Market Perform and lowers the price target from $25 to $22.

EGBN

Keefe, Bruyette & Woods Maintains Market Perform on Eagle Bancorp, Lowers Price Target to $22

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Eastern Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBC#NASDAQ">EBC</a>) with a Outperform and lowers the price target from $22 to $20.

Keefe, Bruyette & Woods Maintains Outperform on Eastern Bankshares, Lowers Price Target to $20

Nocera, Inc., a Nevada corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) ("Nocera" or the "Company"), a fully integrated sustainable seafood company focusing on manufacturing and operating land-based Recirculatory Aquaculture Systems ("RASs"), today announced that it received a letter from the Nasdaq Stock Market LLC ("Nasdaq") dated April 24, 2025, notifying the Company that, because it has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2024 (the "Form 10-K"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission (the "SEC").
The Company is working diligently to complete the Form 10-K and intends to submit a compliance plan within the required timeframe. Nocera is committed to filing the Form 10-K as soon as practicable to maintain compliance with Nasdaq's continued listing requirements.
 &nbsp;

NCRA

Nocera Receives Nasdaq Non-Compliance Notice For Delayed Annual Report Filing

RBC Capital analyst Karl Shepard reiterates Berkshire Hills Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHLB#NYSE">BHLB</a>) with a Sector Perform and maintains $31 price target.

BHLB

RBC Capital Reiterates Sector Perform on Berkshire Hills Bancorp, Maintains $31 Price Target

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains Customers Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) with a Market Perform and lowers the price target from $67 to $65.

CUBI

Keefe, Bruyette & Woods Maintains Market Perform on Customers Bancorp, Lowers Price Target to $65

Macro Economic Events

Economics

Oil is trading lower. The commodity has been under pressure amid uncertainty and OPEC+ output increase plans.

Keefe, Bruyette &amp; Woods analyst Christopher O'Connell maintains Bankwell Finl Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWFG#NASDAQ">BWFG</a>) with a Outperform and raises the price target from $40 to $42.

BWFG

Keefe, Bruyette & Woods Maintains Outperform on Bankwell Finl Gr, Raises Price Target to $42

RBC Capital analyst Gregory Renza reiterates BeiGene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) with a Outperform and maintains $312 price target.

RBC Capital Reiterates Outperform on BeiGene, Maintains $312 Price Target

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Atlantic Union Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUB#NYSE">AUB</a>) with a Market Perform and lowers the price target from $40 to $33.

Keefe, Bruyette & Woods Maintains Market Perform on Atlantic Union Bankshares, Lowers Price Target to $33

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 5 years by 11.64% on an annualized basis producing an average annual return of 25.75%. Currently, Taiwan Semiconductor has a market capitalization of $855.68 billion. 
Buying $100 In TSM: If an investor had bought $100 of TSM stock 5 years ago, it would be worth $302.48 today based on a price of $164.98 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745855111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

RBC Capital analyst Conor McNamara maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Outperform and lowers the price target from $24 to $20.

AVTR

RBC Capital Maintains Outperform on Avantor, Lowers Price Target to $20

Market Summary

NVDA

Benzinga Market Summary: S&P And Nasdaq Drop As NVIDIA Falls On Reports Huawei Has Developed Competing AI Chip, Oil Slips, Bernstein Upgrades Boeing Stock

RBC Capital analyst Matthew Swanson maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Outperform and lowers the price target from $40 to $30.

ZETA

RBC Capital Maintains Outperform on Zeta Global Holdings, Lowers Price Target to $30

RBC Capital analyst Nik Modi reiterates Reynolds Consumer Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REYN#NASDAQ">REYN</a>) with a Sector Perform and maintains $30 price target.

REYN

RBC Capital Reiterates Sector Perform on Reynolds Consumer Prods, Maintains $30 Price Target

RBC Capital analyst Nik Modi reiterates Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) with a Sector Perform and maintains $9 price target.

RBC Capital Reiterates Sector Perform on Newell Brands, Maintains $9 Price Target

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) has outperformed the market over the past 20 years by 5.27% on an annualized basis producing an average annual return of 13.29%. Currently, F5 has a market capitalization of $15.49 billion. 
Buying $100 In FFIV: If an investor had bought $100 of FFIV stock 20 years ago, it would be worth $1,197.31 today based on a price of $267.06 for FFIV at the time of writing.
<h3>F5's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745854218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FFIV

Here's How Much You Would Have Made Owning F5 Stock In The Last 20 Years

Shares of Cantor Equity Partners Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) have soared 202% to $32.76 over the past week, fueled by news of a <a href="https://www.benzinga.com/news/25/04/45010785/cantor-equity-partners-cep-stock-is-up-200-this-week-whats-happening">merger</a> with newly formed Bitcoin-focused firm Twenty One.
What To Know: The combined company, valued at $3.6 billion, is set to become the third-largest public holder of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), behind only <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45039399/strategy-buys-15355-bitcoin-for-142-billion-year-to-date-btc-yield-hits-137">Strategy</a> and Tether. Twenty One is backed by Tether, SoftBank and Jack Mallers—who will step in as CEO following the merger.
Currently, Twenty One holds 42,000 Bitcoin and has ambitious plans to continue accumulating. It recently raised $585 million to bolster its Bitcoin acquisitions and support operations. 
The firm will focus on building Bitcoin-native financial products, media platforms, and capital market tools, with unique metrics such as &#8220;Bitcoin Per Share&#8221; driving its strategy.
Once the merger is finalized, the company's shares will trade on the Nasdaq under the new ticker symbol &#8220;XXI.&#8221; The transaction still requires shareholder approval but signals a major new force in the Bitcoin investment landscape.
Read Also: <a href="https://www.benzinga.com/news/global/25/04/45038430/massive-power-outages-hit-spain-portugal-snarling-travel-investigations-into-cause-underway">Massive Power Outages Hit Spain, Portugal Snarling Travel: Investigations Into Cause Underway</a>
<h2 class="wp-block-heading">How To Buy CEP Stock</h2>
By now you're likely curious about how to participate in the market for Cantor Equity Partners &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Cantor Equity Partners, which is trading at $30.84 as of publishing time, $100 would buy you 3.05 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CEP has a 52-week high of $39.29 and a 52-week low of $9.99.

$BTC

Why Cantor Equity Partners (CEP) Stock Is Up 200% Over The Past Week

Health Care

Press Releases

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Management

Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

Earnings

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

Akero Therapeutics

Alvotech

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

ImmunityBio

Immunovant

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Stifel

Citizens Capital Markets

Jefferies

HC Wainwright & Co.

JMP Securities

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">전고체 배터리 산업화</a> 계약을 체결했다고 발표한 후 64.34% 급등했다.</li>
<li>랜티우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)의 주가는 전문 <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">진단 방사성 의약품</a>에 대한 지불 개선을 위한 CMS 제안 이후 55.93% 급등했다.</li>
<li>선런(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)의 주가는 37.59% 상승했다. 최근 CPI 데이터에 따라 더 넓은 산업 분야의 기업 주가가 상승했기 때문이다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>)의 주가는 화농한선염과 아토피성 피부염에 대한 임상 2상을 확대해 <a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener">안전성 및 유효성</a>에 대한 중간 검토를 거쳐 중추적 연구로 보다 신속하게 진행하겠다는 의사를 밝힌 뒤 37.38% 상승했다.</li>
<li>아포지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)의 주식은 35.68% 급등했다.</li>
<li>조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)은 회사가 <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">물을 유일한 부산물</a>로 사용하여 523마일을 수소 전기 항공 택시 시연차로 성공적으로 비행했다고 발표한 후 주가는 29.10% 상승했다.</li>
<li>크리네틱스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>)은 JP모건이 <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 47달러에서 54달러로</a> 상향 조정한 후 주가는 21.18% 상승했다.</li>
<li>다인 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>)은 JP모건이 주식에 대해 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 39달러에서 43달러로</a> 높인 후 주가는 19.75% 상승했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 지난주 17.24% 급등했다.</li>
<li>플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주가는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 소비자물가지수(CPI) 발표</a> 이후 전기차 관련주가 상승하면서 16.51% 상승했다. 미국 에너지부는 또한 폐쇄되었거나 위험에 처한 11개의 자동차 시설을 전기 자동차와 공급망 제조를 위해 전환하는 데 17억 달러를 투자한다고 발표했다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 15.56% 상승했다. 6월 중국의 수출이 증가한 것을 계기로 중국 관련 주식이 상승했다.</li>
</ol>
기타 읽어볼 만한 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%eb%b0%94%ec%9d%b4%eb%91%90%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-11%ea%b0%9c%ec%9d%98-%eb%8c%80/" target="_blank" rel="noopener">리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스와 델타 항공은 지난주 최악의 성과를 보인 10대 대형주 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of QuantumScape
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Crinetics Pharmaceuticals

뉴스

에 대한 최신 뉴스 Crinetics Pharmaceuticals (NASDAQ:CRNX) 주식

월요일, 7월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌